Literature DB >> 12917763

Barrett's esophagus: model of neoplastic progression.

Stig Ramel1.   

Abstract

Human cancer progression is characterized by clonal expansion of cells with accumulated genetic errors. Invasive carcinomas contain all the genetic errors that were acquired during neoplastic progression and then continue to accumulate further abnormalities, leading to tumor heterogeneity. Many investigations of human cancer have given valuable insights in genetic abnormalities important for tumor biology. Early events responsible for neoplastic progression, however, are often impossible to investigate in invasive cancers because the premalignant tissue in which the tumors develop are often overgrown and the premalignant conditions cannot be studied in vivo because they are either not detected owing to lack of symptoms or are removed before cancer develops. Unlike many other premalignant conditions Barrett's esophagus is often associated with symptoms leading to diagnosis at an early stage before cancer develops, and the premalignant epithelium is seldom removed at an early stage of cancer progression. Furthermore, in patients who present with invasive carcinoma the tumor is often surrounded by premalignant epithelium, which is available for further investigations. Therefore Barrett's esophagus is an excellent model in which to study the early events of neoplastic progression. It may not only contribute to a better understanding of the neoplastic process but also provide a base for safer assessment of cancer risk during surveillance for early detection of esophageal adenocarcinoma.

Entities:  

Mesh:

Year:  2003        PMID: 12917763     DOI: 10.1007/s00268-003-7053-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  73 in total

1.  17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus.

Authors:  P C Galipeau; D S Cowan; C A Sanchez; M T Barrett; M J Emond; D S Levine; P S Rabinovitch; B J Reid
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

3.  Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus.

Authors:  M B Fennerty; R E Sampliner; D Way; R Riddell; K Steinbronn; H S Garewal
Journal:  Gastroenterology       Date:  1989-10       Impact factor: 22.682

4.  Barrett esophagus: the columnar-epithelial-lined lower esophagus.

Authors:  J N Burgess; W S Payne; H A Andersen; L H Weiland; H C Carlson
Journal:  Mayo Clin Proc       Date:  1971-11       Impact factor: 7.616

Review 5.  The molecular biology of esophageal carcinoma.

Authors:  S J Meltzer
Journal:  Recent Results Cancer Res       Date:  1996

6.  17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy.

Authors:  P L Blount; P C Galipeau; C A Sanchez; K Neshat; D S Levine; J Yin; H Suzuki; J M Abraham; S J Meltzer; B J Reid
Journal:  Cancer Res       Date:  1994-05-01       Impact factor: 12.701

7.  Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms.

Authors:  M T Barrett; P C Galipeau; C A Sanchez; M J Emond; B J Reid
Journal:  Oncogene       Date:  1996-05-02       Impact factor: 9.867

Review 8.  Malignant Barrett's oesophagus.

Authors:  H Li
Journal:  Eur J Cancer Prev       Date:  1993-01       Impact factor: 2.497

Review 9.  Prognostic value of p53 in Barrett's oesophagus.

Authors:  K K Krishnadath; M van Blankenstein; H W Tilanus
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-01       Impact factor: 2.566

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  2 in total

Review 1.  Risk factors for neoplastic progression in Barrett's esophagus.

Authors:  Elizabeth F Wiseman; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

2.  Proteomic analysis of SEG-1 human Barrett's-associated esophageal adenocarcinoma cells treated with keyhole limpet hemocyanin.

Authors:  Linda Vona-Davis; Timothy Vincent; Sara Zulfiqar; Barbara Jackson; Dale Riggs; David W McFadden
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.